
Jaguar Health, Inc.
96
Recent developments include Q3 2026 financial results reporting, corporate actions such as reverse stock split approval and preferred stock conversion, product launches, and advancement of clinical programs.
- Jaguar Health reported third quarter 2026 financial results and announced plans for a mid-2027 NDA filing for its lead product Mytesi [N1].
- Stockholders approved a reverse stock split and warrant repricing at the November 6, 2026 special meeting [N2].
- The company announced the automatic conversion of Series R Convertible Preferred Stock into common stock on November 2, 2026, significantly increasing shares outstanding [N3].
- Jaguar Health adjusted share reserves under its 2014 Stock Incentive Plan as of October 29, 2026 [N4].
- Shares rose following Napo's presentation of the intestinal failure program at an Abu Dhabi conference in October 2026 [N5].
- Jaguar Health was featured among five biotech stocks making headlines in September 2026 [N6].
- The stock price plunged after a rally in September 2026 amid focus on reverse stock split and FDA fee waivers [N7].
- The company reported Q3 2025 earnings and provided operational updates in May 2026 [N8].
Jaguar Health, Inc. operates in the biopharmaceutical sector with a focus on gastrointestinal health products for humans and animals. Its lead human health product, Mytesi, is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also markets Canalevia-CA1 for chronic inflammatory diarrhea in dogs. Jaguar Health's business model includes licensing agreements, notably with Woodward Specialty LLC, which holds exclusive commercialization rights for Mytesi and Canalevia in the U.S. The company invests in research and development, clinical trials, regulatory approvals, and commercialization activities. Jaguar Health faces operational challenges including limited operating history, ongoing losses, dependence on a few products and partners, regulatory risks, and the need for additional capital. The company has recently undertaken corporate actions such as reverse stock splits and preferred stock conversions that have materially affected its capital structure.
Jaguar Health, Inc. is a biopharmaceutical company focused on gastrointestinal health products for human and animal use, including the FDA-approved drug Mytesi and the conditionally approved Canalevia-CA1 for dogs. The company has a limited operating history and has incurred significant losses, with substantial doubt about its ability to continue as a going concern due to cash constraints. Jaguar Health has licensed key products to Woodward Specialty LLC and continues to invest in research, development, and commercialization efforts. Recent corporate actions include a reverse stock split, warrant repricing, and preferred stock conversion, significantly increasing the share count. Financial figures are summarized from the latest SEC filings and are provided for informational purposes only — not financial advice.
Jaguar Health's focused portfolio of gastrointestinal health products, including Mytesi and Canalevia-CA1, addresses niche markets with unmet needs. The licensing agreement with Woodward Specialty LLC provides upfront and milestone payments, supporting revenue generation. The company is advancing clinical programs and regulatory filings, including a planned mid-2027 NDA filing, which could expand product indications. Adoption of AI platforms for treatment development and recent product launches in companion animal health demonstrate innovation and diversification efforts. Corporate actions such as reverse stock splits and warrant repricing may improve capital structure and shareholder value.
Jaguar Health has a limited operating history and has incurred significant losses, with substantial doubt about its ability to continue as a going concern due to insufficient cash resources. The company depends heavily on a small number of products and partners, with commercialization risks and regulatory uncertainties. Competition in pharmaceutical markets is significant, and reliance on third-party manufacturers and suppliers poses operational risks. The recent increase in share count through preferred stock conversion and other issuances may dilute existing shareholders. The need for substantial additional capital to fund ongoing operations and clinical trials presents financial risk.
Jaguar Health's moat is primarily based on its proprietary pharmaceutical products targeting niche gastrointestinal conditions in humans and animals, including FDA-approved Mytesi and conditionally approved Canalevia-CA1. The company holds patents and licenses that provide some protection, though these are largely formulation or method-of-use patents which may not fully prevent competition. Its licensing agreement with Woodward Specialty LLC for commercialization rights in the U.S. adds a strategic partnership element. However, the company faces competition from other pharmaceutical firms and relies on third-party manufacturers and suppliers, which may limit its competitive advantage.
• Limited Operating History and Profitability: Jaguar Health has a limited operating history and has incurred significant losses, with no assurance of achieving or sustaining profitability.
• Going Concern Uncertainty: The company has substantial doubt about its ability to continue as a going concern due to insufficient cash resources to fund operations through March 2027.
• Dependence on Key Products and Partners: Revenue and future prospects depend heavily on Mytesi and Canalevia-CA1, and the success of licensee Woodward Specialty LLC.
• Regulatory and Commercialization Risks: Obtaining regulatory approvals for new indications and products is uncertain, and market acceptance is not guaranteed.
• Competition and Intellectual Property: The company faces competition from other pharmaceutical companies and holds patents that may not fully prevent competitors from using similar drugs for other uses.
• Manufacturing and Supply Chain Risks: Dependence on third-party manufacturers and suppliers for active pharmaceutical ingredients and finished products creates operational risks.
• Capital and Dilution Risks: The company requires substantial additional capital for operations and development, with recent corporate actions significantly increasing share count and diluting existing shareholders.
Business trends: Continued focus on gastrointestinal health products with licensing partnerships and clinical development advancing regulatory filings.
Execution milestones: Mid-2027 NDA filing planned, ongoing commercialization efforts, and corporate restructuring including reverse stock split and preferred stock conversion.
Key risks: Limited operating history with ongoing losses, going concern uncertainty, dependence on few products and partners, regulatory and commercialization challenges, and capital dilution risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Jaguar Health, Inc. is a biopharmaceutical company focused on research, development, and commercialization of prescription drugs and non-prescription products primarily in gastrointestinal health for human and animal health.
- The company merged with Napo Pharmaceuticals Inc. in 2017 and has since focused on its lead prescription drug product Mytesi, approved by the FDA for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
- Jaguar Health also commercializes Canalevia-CA1, a conditionally approved prescription drug for chronic inflammatory diarrhea (CID) in dogs, launched in December 2021.
- The company entered into a license agreement on January 12, 2026, granting Woodward Specialty LLC exclusive rights to commercialize Mytesi and Canalevia products in the United States, receiving upfront and potential milestone payments.
- Jaguar Health has a limited operating history and has incurred significant losses, with net comprehensive losses of $54.4 million in 2025 and $39.0 million in 2024, and a stockholder's deficit of $18.7 million as of December 31, 2025.
- The company reported Q3 2026 revenue of $2.343 million and a basic and diluted EPS of -$9.23 per share as of September 30, 2026.
- As of September 30, 2026, Jaguar Health had cash and cash equivalents of approximately $5.53 million, current assets of $16.39 million, current liabilities of $12.83 million, a current ratio of 1.28, and a cash ratio of 0.43.
- The company faces substantial doubt about its ability to continue as a going concern due to insufficient cash resources to fund operations through March 2027.
- Jaguar Health plans to continue investing in research and development, clinical trials, regulatory approvals, and commercialization efforts for its current and future products including Mytesi, NP-300, Canalevia-CA1, and Gelclair.
- The company has approximately 13.3 million shares of common stock outstanding following the automatic conversion of Series R Preferred Stock into common stock on November 2, 2026, which significantly increased share count and diluted existing stockholders.
- Jaguar Health's business risks include dependence on a limited number of products and partners, regulatory approval uncertainties, competition in pharmaceutical markets, reliance on third-party manufacturers and suppliers, and the need for substantial additional capital.
- Recent corporate actions include approval of a reverse stock split and warrant repricing by stockholders in November 2026, automatic conversion of Series R Preferred Stock, and share reserve adjustments to the 2014 Stock Incentive Plan.
- The company is advancing its intestinal failure program and plans a mid-2027 NDA filing for its lead product, as reported in Q3 2026 financial results.
- Jaguar Health has launched Neonorm Dog for companion animal gut health and plans to adopt AI platforms for Crofelemer in treating intestinal failure.
- The company has a workforce of 47 employees as of December 31, 2025, including personnel with advanced degrees in medical and veterinary fields, and operates offices in San Francisco and Italy.
- Jaguar Health's financial figures and liquidity ratios are summarized from the latest SEC filings and provided for informational purposes only, not financial advice.
Generated 2026-11-17
- S1 | 2026-04-07 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-11-17 | www.nasdaq.com | Jaguar Health, Inc. Reports Third Quarter 2026 Financial Results and Plans mid-2027 NDA Filing | https://www.nasdaq.com/articles/jaguar-health-inc-reports-third-quarter-2026-financial-results-and-plans-mid-2027-nda
- N2 | 2026-11-07 | www.nasdaq.com | Jaguar Health, Inc. Stockholders Approve Reverse Stock Split and Warrant Repricing at November 6, 2026 Special Meeting | https://www.nasdaq.com/articles/jaguar-health-inc-stockholders-approve-reverse-stock-split-and-warrant-repricing-november
- N3 | 2026-11-03 | www.nasdaq.com | Jaguar Health, Inc. Announces Automatic Conversion of Series R Convertible Preferred Stock | https://www.nasdaq.com/articles/jaguar-health-inc-announces-automatic-conversion-series-r-convertible-preferred-stock
- N4 | 2026-10-29 | www.nasdaq.com | Jaguar Health, Inc. Announces Share Reserve Adjustment to 2014 Stock Incentive Plan | https://www.nasdaq.com/articles/jaguar-health-inc-announces-share-reserve-adjustment-2014-stock-incentive-plan
- N5 | 2026-10-06 | www.nasdaq.com | Jaguar Health Shares Jump As Napo Showcases Intestinal Failure Program At Abu Dhabi Conference | https://www.nasdaq.com/articles/jaguar-health-shares-jump-napo-showcases-intestinal-failure-program-abu-dhabi-conference
- N6 | 2026-09-25 | www.nasdaq.com | 5 Biotech Stocks Making Headlines - ADRX, CNSY, JAGX, AGL, ONCO | https://www.nasdaq.com/articles/5-biotech-stocks-making-headlines-adrx-cnsy-jagx-agl-onco
- N7 | 2026-09-23 | www.nasdaq.com | Jaguar Health Plunges After Tuesday Rally; Reverse Stock Split And FDA Fee Waivers In Focus | https://www.nasdaq.com/articles/jaguar-health-plunges-after-tuesday-rally-reverse-stock-split-and-fda-fee-waivers-focus
- N8 | 2026-05-21 | www.nasdaq.com | Jaguar Health (JAGX) Q3 2025 Earnings Transcript | https://www.nasdaq.com/articles/jaguar-health-jagx-q3-2025-earnings-transcript
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


